Invesco LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Invesco LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, HoldingsChannel reports. The fund acquired 4,448 shares of the medical research company’s stock, valued at approximately $339,000.

Several other institutional investors also recently bought and sold shares of the company. Sequoia Financial Advisors LLC increased its holdings in Edwards Lifesciences by 11.4% in the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 941 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Edwards Lifesciences by 34.7% during the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock worth $204,000 after purchasing an additional 448 shares during the period. Covestor Ltd raised its stake in Edwards Lifesciences by 18.2% during the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock worth $144,000 after purchasing an additional 188 shares during the period. Mather Group LLC. raised its stake in shares of Edwards Lifesciences by 53.5% in the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp raised its stake in shares of Edwards Lifesciences by 3.1% in the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after acquiring an additional 19,798 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.2 %

Shares of EW stock opened at $89.20 on Tuesday. The stock has a market cap of $53.69 billion, a price-to-earnings ratio of 38.78, a price-to-earnings-growth ratio of 4.47 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm’s 50 day moving average price is $90.07 and its two-hundred day moving average price is $77.92.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 earnings per share. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.27% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. Citigroup upped their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Royal Bank of Canada raised their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday. Oppenheimer raised their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.